Abstract
The development oflineage specific monoclonal antibodies has provided a means of identifying lymphoid lineage and the particular stage of differentiation of the leukemic cells [1–3]. Moreover, the application of several sophisticated investigations (dual fluorescence analysis, cytogenetic and genotypical studies) has led to a number of reports describing acute leukemias with the characteristics of two or more hematopoietic lineages [4–7]. A large number of studies analysing the expression of myeloid associated antigens (CD 13, CD33) in ALL (My + ALL) and T lymphoid antigens (CD2, CD3) in acute myeloblastic leukaemia (AML) [8–10) have been reported. Some Authors [11–14J have already emphasized the clinical significance of the co expression of myeloid and lymphoid antigens in the leukemic cells. This report describes the immunological characteristics of leukemic cells from a series of 68 ALL patients observed in our institution, evaluating a) the ALL immunophenotype at diagnosis and in relapse, and b) the possible prognostic significance of the expression of myeloid-associated antigens in ALL cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
